IDEXX Laboratories, Inc. — Q2 2022 Form 10-Q Summary
Business context and reporting period
IDEXX develops diagnostic products and services for companion-animal veterinary, livestock, poultry and dairy, water-testing, and human medical diagnostics markets. This unaudited Form 10-Q covers the three and six months ended June 30, 2022, compared with the corresponding 2021 periods.
- Primary segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other.
- CAG represented approximately 91% of second-quarter revenue and remained the principal growth driver.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Year-over-year change | Six months ended June 30, 2022 | Year-over-year change |
|---|---|---|---|---|
| Total revenue | $860.5 million | 4.2% | $1.697 billion | 5.8% |
| Organic revenue growth | 6.5% | — | 7.2% | — |
| Gross profit | $514.0 million | 5.1% | $1.013 billion | 5.5% |
| Gross margin | 59.7% | Up 50 bps | 59.7% | Down 20 bps |
| Income from operations | $179.1 million | Down 30.9% | $427.4 million | Down 15.7% |
| Operating margin | 20.8% | Down from 31.4% | 25.2% | Down from 31.6% |
| Net income attributable to IDEXX | $132.0 million | Down 34.9% | $325.9 million | Down 19.9% |
| Diluted EPS | $1.56 | Down from $2.34 | $3.82 | Down from $4.69 |
- CAG revenue increased 5.2% in the second quarter and 7.4% for the first six months; organic growth was 7.3% and 8.7%, respectively.
- Water revenue increased 5.4% in the quarter and 6.1% year to date, supported by pricing and testing volumes.
- LPD revenue declined 10.8% in the quarter and 16.5% year to date, primarily because of lower swine-testing demand in China and reduced African Swine Fever testing.
- Other revenue declined 25.0% in the quarter and 27.8% year to date, primarily because of lower OPTI COVID-19 PCR testing revenue.
- Research and development expense increased by $85.5 million in the quarter and $88.1 million year to date, including $80 million of expense for two intellectual-property licensing arrangements with no alternative future use.
- Operating cash flow was $180.6 million for the first six months, down from $358.4 million in 2021. The decline reflected lower net income, higher inventory investment, and unfavorable changes in other operating assets and liabilities.
- Capital expenditures were $61.9 million year to date. Management expects approximately $180 million of full-year 2022 capital spending.
- Cash and cash equivalents were $114.4 million at June 30, 2022, compared with $144.5 million at December 31, 2021.
- Debt included $611.0 million outstanding under the revolving credit facility and $768.0 million of long-term debt. Remaining credit-facility availability was $387.6 million, and the company was in compliance with its 3.5-to-1 leverage covenant.
- Reported gross debt to adjusted EBITDA was 1.37-to-1 and net debt to adjusted EBITDA was 1.26-to-1, based on trailing twelve-month adjusted EBITDA of $1.009 billion.
Material changes versus the prior comparable periods
- Revenue growth remained positive, led by recurring CAG diagnostics revenue, instrument placements, software, reference-laboratory services, and pricing.
- Profitability declined materially because of the $80 million licensing expense, higher personnel and commercial investments, inflationary product, freight and labor costs, and higher taxes.
- The effective tax rate increased to 22.9% from 19.5% for the quarter and to 21.0% from 17.3% for the six-month period, primarily because of higher international taxes and lower share-based compensation tax benefits.
- The stronger U.S. dollar reduced second-quarter reported revenue growth by 3.3 percentage points and six-month growth by 2.6 percentage points.
- The company borrowed $537.5 million net under its revolving credit facility, repurchased $573.1 million of common stock for cash, and paid off $75.0 million of 2022 senior notes during the first six months.
- Inventory increased to $332.6 million from $269.0 million at year-end, reflecting efforts to maintain product availability and inventory associated with the ProCyte One analyzer.
- In June 2022, IDEXX decided to wind down and liquidate its sole Russian subsidiary. Direct Russian operations were not material to the financial statements; limited third-party distribution is expected to continue.
Guidance, outlook, commentary, and risks
- Management expects supply-chain constraints, logistics delays, inflationary pressure, and potential fuel shortages to continue during 2022, although it reported continued high product availability and customer service.
- Management expects comparisons for LPD to improve in the second half of 2022, but demand remains affected by Chinese pork prices, government requirements, and disease-management practices.
- Based on stated currency assumptions, management expects the stronger dollar to reduce second-half 2022 revenue by approximately $69 million, operating profit by approximately $13 million, and diluted EPS by approximately $0.12 versus the prior-year period. Hedging is expected to offset approximately $20 million of operating profit and $0.18 of EPS impact.
- Key risks include the war in Ukraine, sanctions and geopolitical instability, COVID-19 effects, supply-chain disruption, inflation, foreign-exchange volatility, cybersecurity, and weaker veterinary or livestock testing demand.
- IDEXX faces ongoing litigation concerning alleged underpayment of royalties under an expired patent license. The plaintiff claims approximately $50 million, while the company has accrued $27.5 million and is appealing an adverse trial-court ruling.
- The company expects current cash, operating cash flow, and committed borrowing capacity to fund operations, capital requirements, and anticipated growth needs for at least the next twelve months.
Most important facts for investors to verify
- Whether recurring CAG diagnostics growth and veterinary clinic demand offset weaker clinical-visit trends and foreign-exchange headwinds.
- The sustainability of operating margins after the nonrecurring $80 million licensing expense and amid inflation and supply-chain costs.
- Execution of the ProCyte One launch, instrument placements, and expansion of software and recurring-revenue offerings.
- LPD recovery prospects, particularly in China, and the degree to which COVID-related OPTI revenue declines persist.
- Debt reduction, share-repurchase spending, liquidity, and compliance with the 3.5-to-1 leverage covenant.
- Actual 2022 currency effects compared with management’s assumptions and the effectiveness of hedging activities.
- Potential outcomes and additional financial exposure from the royalty litigation and the Russian operations wind-down.